Comparing Factor Use and Bleed Rates in U.S. Hemophilia A Patients Receiving Prophylaxis with 3 Different Long-Acting Recombinant Factor VIII Products

BACKGROUND: Recombinant factor VIII (rFVIII) products have been developed with improved pharmacokinetics, offering some patients the potential to extend dosing intervals, thereby reducing their dosing frequency while minimizing the occurrence of bleeding events. No clinical trials have been conducte...

Descripción completa

Detalles Bibliográficos
Autores principales: Simpson, Mindy L., Desai, Vidhi, Maro, Géraldine S., Yan, Songkai
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Academy of Managed Care Pharmacy 2020
Materias:
Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10391023/
https://www.ncbi.nlm.nih.gov/pubmed/32020842
http://dx.doi.org/10.18553/jmcp.2020.19318

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10391023/
https://www.ncbi.nlm.nih.gov/pubmed/32020842
http://dx.doi.org/10.18553/jmcp.2020.19318

Ejemplares similares